Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score

Piiha Lotta Jerevall, Jane Brock, Juan Palazzo, Tad Wieczorek, Michael Misialek, Anthony J. Guidi, Yun Wu, Mark G. Erlander, Yi Zhang, Catherine A. Schnabel, Paul E. Goss, Nora Horick, Dennis C. Sgroi

Research output: Contribution to journalArticle

Abstract

Purpose: A recent comparison of the prognostic accuracy of Breast Cancer Index (BCI) and the Recurrence Score (RS) showed that BCI was more precise than RS. BCI identified a subset of RS low and intermediate risk patients with clinically relevant elevated rates of distant recurrences (DR). The current study analyzed the correlation of BCI and RS risk classification to clinical and pathological parameters and further examined the re-categorization between the two risk group indices in a multi-institutional cohort of hormone receptor positive (HR+) breast cancer patients. Methods: 560 women with HR+, lymph node-negative breast cancer who underwent testing with RS as part of their routine clinical care were included in the final analysis. Individual risk was assessed using predefined categories of RS and BCI (Low, Intermediate and High, respectively). Correlations between BCI, RS, and standard clinical-pathological prognostic factors were examined, and re-categorization of risk groups between BCI and RS was analyzed. Results: An overall significant association between histological tumor grade and RS or BCI was observed with high-grade tumors more prevalent among RS and BCI high-risk patients. The invasive ductal carcinoma histologic subtype was associated with 98% and 93% of high-risk RS and BCI cases, respectively. The invasive lobular subtype accounted for 0% and 6% of high-risk RS and BCI cases, respectively. A poor agreement between the two biomarker risk group indices was demonstrated with more than 51% of the total cohort stratified differently between BCI and RS. As compared with RS, BCI stratified fewer patients into the intermediate-risk group (29% vs. 39%, BCI and RS, respectively) and more patients into the high-risk group (19% vs. 7%, BCI and RS, respectively). Subsets of both RS low- and intermediate-risk patients were identified by BCI as high risk. Conclusions: In this clinical series, BCI and RS risk groups demonstrated a significant association with histological tumor grade. BCI showed a modest correlation with tumor size and no correlation with age, while RS showed no correlation with tumor size or age. Compared with RS, BCI classifies fewer intermediate risk patients, identifies subsets of low and intermediate RS risk patients as high-risk, and provides distinct individualized risk assessment for patients with early-stage breast cancer.

Original languageEnglish (US)
Pages (from-to)375-383
Number of pages9
JournalBreast Cancer Research and Treatment
Volume173
Issue number2
DOIs
StatePublished - Jan 30 2019

Fingerprint

Hormones
Breast Neoplasms
Recurrence
Neoplasms
Ductal Carcinoma

Keywords

  • Biomarkers
  • Breast cancer
  • Prognosis
  • Risk prediction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score. / Jerevall, Piiha Lotta; Brock, Jane; Palazzo, Juan; Wieczorek, Tad; Misialek, Michael; Guidi, Anthony J.; Wu, Yun; Erlander, Mark G.; Zhang, Yi; Schnabel, Catherine A.; Goss, Paul E.; Horick, Nora; Sgroi, Dennis C.

In: Breast Cancer Research and Treatment, Vol. 173, No. 2, 30.01.2019, p. 375-383.

Research output: Contribution to journalArticle

Jerevall, PL, Brock, J, Palazzo, J, Wieczorek, T, Misialek, M, Guidi, AJ, Wu, Y, Erlander, MG, Zhang, Y, Schnabel, CA, Goss, PE, Horick, N & Sgroi, DC 2019, 'Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score', Breast Cancer Research and Treatment, vol. 173, no. 2, pp. 375-383. https://doi.org/10.1007/s10549-018-5013-6
Jerevall, Piiha Lotta ; Brock, Jane ; Palazzo, Juan ; Wieczorek, Tad ; Misialek, Michael ; Guidi, Anthony J. ; Wu, Yun ; Erlander, Mark G. ; Zhang, Yi ; Schnabel, Catherine A. ; Goss, Paul E. ; Horick, Nora ; Sgroi, Dennis C. / Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score. In: Breast Cancer Research and Treatment. 2019 ; Vol. 173, No. 2. pp. 375-383.
@article{1ca1243fba84436dbe271d7faf46a2fc,
title = "Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score",
abstract = "Purpose: A recent comparison of the prognostic accuracy of Breast Cancer Index (BCI) and the Recurrence Score (RS) showed that BCI was more precise than RS. BCI identified a subset of RS low and intermediate risk patients with clinically relevant elevated rates of distant recurrences (DR). The current study analyzed the correlation of BCI and RS risk classification to clinical and pathological parameters and further examined the re-categorization between the two risk group indices in a multi-institutional cohort of hormone receptor positive (HR+) breast cancer patients. Methods: 560 women with HR+, lymph node-negative breast cancer who underwent testing with RS as part of their routine clinical care were included in the final analysis. Individual risk was assessed using predefined categories of RS and BCI (Low, Intermediate and High, respectively). Correlations between BCI, RS, and standard clinical-pathological prognostic factors were examined, and re-categorization of risk groups between BCI and RS was analyzed. Results: An overall significant association between histological tumor grade and RS or BCI was observed with high-grade tumors more prevalent among RS and BCI high-risk patients. The invasive ductal carcinoma histologic subtype was associated with 98{\%} and 93{\%} of high-risk RS and BCI cases, respectively. The invasive lobular subtype accounted for 0{\%} and 6{\%} of high-risk RS and BCI cases, respectively. A poor agreement between the two biomarker risk group indices was demonstrated with more than 51{\%} of the total cohort stratified differently between BCI and RS. As compared with RS, BCI stratified fewer patients into the intermediate-risk group (29{\%} vs. 39{\%}, BCI and RS, respectively) and more patients into the high-risk group (19{\%} vs. 7{\%}, BCI and RS, respectively). Subsets of both RS low- and intermediate-risk patients were identified by BCI as high risk. Conclusions: In this clinical series, BCI and RS risk groups demonstrated a significant association with histological tumor grade. BCI showed a modest correlation with tumor size and no correlation with age, while RS showed no correlation with tumor size or age. Compared with RS, BCI classifies fewer intermediate risk patients, identifies subsets of low and intermediate RS risk patients as high-risk, and provides distinct individualized risk assessment for patients with early-stage breast cancer.",
keywords = "Biomarkers, Breast cancer, Prognosis, Risk prediction",
author = "Jerevall, {Piiha Lotta} and Jane Brock and Juan Palazzo and Tad Wieczorek and Michael Misialek and Guidi, {Anthony J.} and Yun Wu and Erlander, {Mark G.} and Yi Zhang and Schnabel, {Catherine A.} and Goss, {Paul E.} and Nora Horick and Sgroi, {Dennis C.}",
year = "2019",
month = "1",
day = "30",
doi = "10.1007/s10549-018-5013-6",
language = "English (US)",
volume = "173",
pages = "375--383",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score

AU - Jerevall, Piiha Lotta

AU - Brock, Jane

AU - Palazzo, Juan

AU - Wieczorek, Tad

AU - Misialek, Michael

AU - Guidi, Anthony J.

AU - Wu, Yun

AU - Erlander, Mark G.

AU - Zhang, Yi

AU - Schnabel, Catherine A.

AU - Goss, Paul E.

AU - Horick, Nora

AU - Sgroi, Dennis C.

PY - 2019/1/30

Y1 - 2019/1/30

N2 - Purpose: A recent comparison of the prognostic accuracy of Breast Cancer Index (BCI) and the Recurrence Score (RS) showed that BCI was more precise than RS. BCI identified a subset of RS low and intermediate risk patients with clinically relevant elevated rates of distant recurrences (DR). The current study analyzed the correlation of BCI and RS risk classification to clinical and pathological parameters and further examined the re-categorization between the two risk group indices in a multi-institutional cohort of hormone receptor positive (HR+) breast cancer patients. Methods: 560 women with HR+, lymph node-negative breast cancer who underwent testing with RS as part of their routine clinical care were included in the final analysis. Individual risk was assessed using predefined categories of RS and BCI (Low, Intermediate and High, respectively). Correlations between BCI, RS, and standard clinical-pathological prognostic factors were examined, and re-categorization of risk groups between BCI and RS was analyzed. Results: An overall significant association between histological tumor grade and RS or BCI was observed with high-grade tumors more prevalent among RS and BCI high-risk patients. The invasive ductal carcinoma histologic subtype was associated with 98% and 93% of high-risk RS and BCI cases, respectively. The invasive lobular subtype accounted for 0% and 6% of high-risk RS and BCI cases, respectively. A poor agreement between the two biomarker risk group indices was demonstrated with more than 51% of the total cohort stratified differently between BCI and RS. As compared with RS, BCI stratified fewer patients into the intermediate-risk group (29% vs. 39%, BCI and RS, respectively) and more patients into the high-risk group (19% vs. 7%, BCI and RS, respectively). Subsets of both RS low- and intermediate-risk patients were identified by BCI as high risk. Conclusions: In this clinical series, BCI and RS risk groups demonstrated a significant association with histological tumor grade. BCI showed a modest correlation with tumor size and no correlation with age, while RS showed no correlation with tumor size or age. Compared with RS, BCI classifies fewer intermediate risk patients, identifies subsets of low and intermediate RS risk patients as high-risk, and provides distinct individualized risk assessment for patients with early-stage breast cancer.

AB - Purpose: A recent comparison of the prognostic accuracy of Breast Cancer Index (BCI) and the Recurrence Score (RS) showed that BCI was more precise than RS. BCI identified a subset of RS low and intermediate risk patients with clinically relevant elevated rates of distant recurrences (DR). The current study analyzed the correlation of BCI and RS risk classification to clinical and pathological parameters and further examined the re-categorization between the two risk group indices in a multi-institutional cohort of hormone receptor positive (HR+) breast cancer patients. Methods: 560 women with HR+, lymph node-negative breast cancer who underwent testing with RS as part of their routine clinical care were included in the final analysis. Individual risk was assessed using predefined categories of RS and BCI (Low, Intermediate and High, respectively). Correlations between BCI, RS, and standard clinical-pathological prognostic factors were examined, and re-categorization of risk groups between BCI and RS was analyzed. Results: An overall significant association between histological tumor grade and RS or BCI was observed with high-grade tumors more prevalent among RS and BCI high-risk patients. The invasive ductal carcinoma histologic subtype was associated with 98% and 93% of high-risk RS and BCI cases, respectively. The invasive lobular subtype accounted for 0% and 6% of high-risk RS and BCI cases, respectively. A poor agreement between the two biomarker risk group indices was demonstrated with more than 51% of the total cohort stratified differently between BCI and RS. As compared with RS, BCI stratified fewer patients into the intermediate-risk group (29% vs. 39%, BCI and RS, respectively) and more patients into the high-risk group (19% vs. 7%, BCI and RS, respectively). Subsets of both RS low- and intermediate-risk patients were identified by BCI as high risk. Conclusions: In this clinical series, BCI and RS risk groups demonstrated a significant association with histological tumor grade. BCI showed a modest correlation with tumor size and no correlation with age, while RS showed no correlation with tumor size or age. Compared with RS, BCI classifies fewer intermediate risk patients, identifies subsets of low and intermediate RS risk patients as high-risk, and provides distinct individualized risk assessment for patients with early-stage breast cancer.

KW - Biomarkers

KW - Breast cancer

KW - Prognosis

KW - Risk prediction

UR - http://www.scopus.com/inward/record.url?scp=85055559303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055559303&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-5013-6

DO - 10.1007/s10549-018-5013-6

M3 - Article

C2 - 30350269

AN - SCOPUS:85055559303

VL - 173

SP - 375

EP - 383

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -